Holen Sie sich die Stockscreener-App
12.84
0.93%
-0.12
Schlusskurs vom Vortag:
$12.96
Offen:
$12.98
24-Stunden-Volumen:
739.98K
Relative Volume:
0.35
Marktkapitalisierung:
$625.86M
Einnahmen:
$15.84M
Nettoeinkommen (Verlust:
$-308.48M
KGV:
-1.9815
EPS:
-6.48
Netto-Cashflow:
$-153.08M
1W Leistung:
-9.45%
1M Leistung:
-13.88%
6M Leistung:
+82.65%
1J Leistung:
+105.11%
1-Tages-Spanne:
$12.53
$13.15
1-Wochen-Bereich:
$12.53
$14.42
52-Wochen-Spanne:
$3.73
$19.18
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Vergleichen Sie QURE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
12.84 | 625.86M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
Huntington's Disease Market Growth to Accelerate in Forecast - openPR
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons - Seeking Alpha
uniQure (QURE) Expected to Announce Earnings on Wednesday - MarketBeat
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66% - Yahoo Finance
24,749 Shares in uniQure (NASDAQ:QURE) Acquired by Palumbo Wealth Management LLC - MarketBeat
uniQure (NASDAQ:QURE) Stock Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
(QURE) Proactive Strategies - Stock Traders Daily
uniQure (NASDAQ:QURE) Stock Price Down 6.7%Should You Sell? - MarketBeat
uniQure (NASDAQ:QURE) Raised to Sell at StockNews.com - MarketBeat
abrdn plc Sells 419,726 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Swelling losses haven't held back gains for uniQure (NASDAQ:QURE) shareholders since they're up 147% over 1 year - Simply Wall St
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four YearsuniQure (NASDAQ:QURE), CSL (OTC:CSLLY) - Benzinga
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B - Quantisnow
uniQure (NASDAQ:QURE) Stock Rating Upgraded by StockNews.com - Defense World
Analysts Set uniQure (NASDAQ:QURE) Price Target at $40.00 - MarketBeat
uniQure Announces Completion of Enrollment in the First - GlobeNewswire
UniQure Advances AMT-191 Trial in Fabry Disease -February 03, 2025 at 12:09 pm EST - Marketscreener.com
uniQure advances gene therapy trial for Fabry disease By Investing.com - Investing.com Australia
uniQure advances gene therapy trial for Fabry disease - Investing.com
Rare Disease Breakthrough: Gene Therapy Trial Shows Promise in Fabry Disease Treatment - StockTitan
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - The Manila Times
uniQure (NASDAQ:QURE) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
HC Wainwright Issues Negative Estimate for uniQure Earnings - MarketBeat
Analysts Set Expectations for uniQure FY2029 Earnings - MarketBeat
uniQure (NASDAQ:QURE) Trading Down 4.8%Should You Sell? - MarketBeat
uniQure Announces Favorable Recommendation from Independent - GlobeNewswire
UniQure Gets Favorable Recommendation From Data Monitoring Committee AMT-162 Trial to Treat Amyotrophic Lateral Sclerosis - Marketscreener.com
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS - The Manila Times
Game-Changing ALS Treatment: uniQure's Gene Therapy Hits Critical Milestone - StockTitan
FY2024 EPS Estimates for uniQure Reduced by HC Wainwright - Defense World
FY2029 Earnings Forecast for uniQure Issued By HC Wainwright - Defense World
HC Wainwright Issues Positive Forecast for uniQure (NASDAQ:QURE) Stock Price - Defense World
H.C. Wainwright sets uniQure stock price target at $70 By Investing.com - Investing.com Australia
The Hidden Gem in Biotechnology? It’s Time to Take Notice - Jomfruland.net
Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts? - Insider Monkey
H.C. Wainwright sets uniQure stock price target at $70 - Investing.com India
uniQure (NASDAQ:QURE) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
12 Most Promising Growth Stocks According to Wall Street Analysts - Insider Monkey
Assenagon Asset Management S.A. Sells 197,775 Shares of uniQure (NASDAQ:QURE) - MarketBeat
Analysts Offer Predictions for uniQure FY2025 Earnings - Defense World
Brokers Offer Predictions for uniQure FY2025 Earnings - MarketBeat
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Uniqure N V-Aktie (QURE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Dec 10 '24 |
Sale |
15.03 |
100,000 |
1,503,000 |
597,915 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 09 '24 |
Sale |
7.63 |
3,418 |
26,079 |
597,915 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Dec 09 '24 |
Sale |
7.55 |
1,796 |
13,560 |
166,713 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):